DexCom, Inc. - Governance & Sustainability

IR Contacts

Sean Christensen

Vice President, Finance and Investor Relations

Matt Carey

Investor Relations Manager

(858) 200-0200
investor-relations@dexcom.com

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options *

News
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote
Events & Presentations

Unsubscribe

1. JAMA. 2017;317(4):371-378.
2. Welsh, J.B. et al (2019). "Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems." Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.

*If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.

Powered By Q4 Inc. 5.83.0.2